E-Buy Home, Inc. (EBYH)

[Bansky]

Strainsforpains, Inc. Shareholder Update . New York, NY, November 7, 2022— STRAINSFORPAINS,INC. ( OTC Markets: EBYH). On November 4, 2022

The Centers for Disease Control and Prevention issued new guidelines for health clinicians on how and when to prescribe opioids for pain relief. This report changes the 2016 recommendations which many doctors and patients criticized as too austere. The 2016 guidelines attempted to restrict the use of opioids and created untreated or undertreated pain. This new plan serves as a roadmap for physicians to navigate how to treat pain and chronic conditions. Although these new guidelines are voluntary they are attempting to not limit what is the best policy for the doctor to prescribe, including alternative pain medications. “

I believe that these new guidelines will not increase doctor’s prescriptions for opioid medicines but rather allow physicians and nurses to start seriously learning about alternatives like medical cannabis, to provide better care and relieve patients pain”, said Y. Simon Shainberg, CEO of Strainsforpains, Inc. “This new focus on individualized care”, said Mr. Shainberg, “will emphasize that treatment in many cases points to evidence that other treatments and approaches are comparable for improving pain and function”. While these guidelines are welcome their impact will depend on other federal and state agency’s responses to them. As such, Mr. Shainberg has been asked to contribute to a request for information (RFI) from the National Institute of Health as to their interest in barriers to research studies on the health effects of cannabis and its constituents. In this regard, Strainsforpains has developed an App for the healthcare community addressing best practices for recommendations of specific cannabis strains for individual pain management. The app will educate doctors, pharmacists, and health professionals as well as chronic pain sufferers with the tools needed to determine effective cannabis usage.

“There is a need for professionals to understand the safety and effectiveness of cannabis for medical indications. A major barrier is lack of knowledge in the field by health professionals”, said Mr. Shainberg. Mr. Shainberg has spent the last 15 years studying the effects of hundreds of cannabis strains on chronic pain sufferers. He is a member of the International Cannabinoid Research Society. “We believe that many patients who are using both THC and CBD in conjunction with opioids often feel far better, with fewer side effects than only using opioids”, said Mr. Shainberg.

Mr. Shainberg advises health professionals that their patients should always be advised to record their experience of use, including side effects observed and views regarding the impact of treatment. Ultimately a medical access program should collect this confidential data. Overview of Strainsforpains, Inc. Please visit our website at http://www.strainsforpains.com/ CDC November 4, 2022 Guidelines

https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1_w

National Institute of Health, National Center for Complimentary and Integrative Health
https://www.nccih.nih.gov/

International Cannabinoid Research Society https://icrs.co/